Gout

John Botson, MD, discusses his study examining real-world pegloticase plus immunomodulation co-therapy using data from an insurance claims database.

At month 6, more patients in the AR882 75 mg cohort demonstrated complete resolution of ≥1 tophus compared with patients in the allopurinol cohort.

In this research presented at ACR 2023, investigators looked at potential factors which could predict flare risk after urate-lowering therapy initiation.

The 2 groups—the active control group who received smartphone notifications about general health advice and the intervention group who receive notifications on adherence-targeted information—did not have significant differences in serum urate levels.

After a 12-week gap, 5% of patients returned to pegloticase and responded well.

In a recent study, participants had highest gout flare rates when serum urate levels were > 10 mg/dL and the lowest gout flare when levels were < 3.9 mg/dL.

Approximately 10% of patients with gout had a concomitant diagnosis of venous thromboembolism among nearly 800,000 hospitalizations in the US.

This new data from ACR 2023 suggests that the guidelines on a healthy diet predominantly based on plants have been confirmed with regard to incident gout.

Receipt of RZV was not associated with an increased risk of incident gout among more than 1,000 adults ≥ 65 years of age who received at least 1 dose of the 2-dose vaccine regimen.

At the follow-up with a study sample of 16.7 million patients, 6.9% of gout patients had chronic opioid use (n = 28,948) while 3.8% of the non-gout patients did.

Lifestyle habits including vegetable consumption and exercise were associated with Gout Impact Scale score.

In this data shown at ACR 2023, the URAT1 inhibitor known as AR882 showed promising phase 2b data for patients with gout.

Richard Johnson, MD, discusses the results of a study from ASN Kidney Week 2023 detailing the effects of urate-lowering therapy on blood pressure among patients with gout.

An analysis of the MIRROR trial from ASN Kidney Week 2023 details the effects of urate-lowering therapy on blood pressure among patients with uncontrolled gout receiving pegloticase plus methotrexate in the phase 4 trial.

In patients initiating allopurinal, adverse events were more common in those receiving concomitant colchicine or nonsteroidal anti-inflammatory drugs compared to those without prophylaxis.

A systematic literature search reported an increase in both publications and cases of spinal gout.

Although the dietary intervention did not significantly reduce overall serum urate, it did decrease levels among those with baseline hyperuricemia.

Despite commonly understood symptoms and efficacious treatments, the stigmatizing nature of gout has caused significant setbacks to curbing its impact on Americans.

Low allopurinol prescription rates and suboptimal dosing are of particular concern in adult patients in Asia with poorly controlled gout.

A systematic review of 11 randomized clinical trials found adults with gout exhibited similar hepatic safety profiles for both febuxostat and allopurinol treatment.

Changes in the serum urate levels, number of gout flares before 1 year of treatment, and tophus were linked to the number of gout flares.

All assessed outcomes revealed the treatment effects were significantly better in the external herbal medicine group compared to the control group.

Study links inflammatory bowel disease diagnosis to increased gout risk, with Crohns disease and ulcerative colitis linked to 68% and 38% increases in likelihood of developing gout, respectively, relative to counterparts without IBD.

Males in the highest serum uric acid tier were significantly more likely to be diagnosed with peripheral artery disease, although a similar trend was not observed in female patients.

The incidences of stroke, ischemic heart disease, or heart failure were slightly higher in patients with gout when compared with controls.